日本臨牀 80/増刊3 臨床胃癌学

出版社: 日本臨牀社
発行日: 2022-03-31
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 臨床胃癌学
電子書籍版: 2022-03-31 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

22,000 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

目次

  • 特集 臨床胃癌学
       ―基礎・臨床の最新動向―

    I. 胃癌の疫学
     1.日本における胃癌の疫学的動向:概論
     2.胃がんの疫学―国際比較と将来展望―
     3.胃癌の危険因子

    II. 胃癌の発癌機序
     1.胃癌の発癌機序と予防:概論
     2.ピロリ菌CagAがんタンパク質によるBRCAness誘導とHit-and-Run型胃発がん
     3.胃癌の浸潤・転移:概論(各臓器転移の臨床的特徴を含む)

    III. 胃癌取扱い規約・胃癌治療ガイドライン
     1.取扱い規約(第15版)とTNM分類(第8版)の比較
     2.胃癌治療ガイドライン:NCCNガイドラインとの違いは何か
     3.早期胃癌に対するESDガイドライン

    IV. 胃癌の検査・診断
     1.胃癌の検査・診断:概論
     2.胃がん検診・スクリーニング
     3.胃癌の内視鏡検査・診断
     4.胃癌の病理検査・診断

    V. 胃癌の治療
     1.外科治療・内視鏡治療
     2.化学療法
     3.高齢者症例に対する胃癌治療
     4.胃癌治療上の栄養管理
     5.緩和医療と疼痛管理

    VI. 胃癌の予防
     1.H.pylori除菌
     2.ABC分類の意義

    VII. 特論
     1.AIによる画像診断
     2.自己免疫性胃炎と胃癌
     3.胃癌治療ガイドラインの市民への啓発
     4.胃粘膜DNAメチル化異常を用いた胃発癌リスク診断
     5.ピロリ感染・除菌診断の最新動向―抗体検査を中心に
     6.胃癌における免疫療法の位置付けと意義、バイオマーカー

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.5 掲載の参考文献
1) 入口陽介 : 胃がん検診の歴史と今後の展望. 胃と腸 53 : 1069-1072, 2018.
2) Sano T, et al : Lymph node metastasis from early gastric cancer : endoscopic resection of tumour. Br J Surg 79 : 241-244, 1992.
3) Gotoda T, et al : Incidence of lymph node metastasis from early gastric cancer : estimation with a large number of cases at two large centers. Gastric Cancer 3 : 219-225, 2000.
5) Cristescu R, et al : Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21 : 449-456, 2015.
6) Yan HHN, et al : A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell 23 : 882-897.e11, 2018.
11) Malfertheiner P, et al : Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66 : 6-30, 2017.
12) Hiroi S, et al : Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan : retrospective observational study and simulation study based on real-world data. BMJ Open 7 : e015855, 2017.

I 胃癌の疫学

P.12 掲載の参考文献
1) International Agency for Research on Cancer : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, volume 61, Schistosomes, Liver Flukes and Helicobacter pylori, p218-220, IARC, Lyon, 1994.
2) Hirayama Y, et al : Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol 29 (Suppl 4) : 16-19, 2014.
3) Ueda J, et al : Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter 19 : 105-110, 2014.
4) 国立がん研究センター : がん情報サービス, がん統計 (ganjoho.jp).
5) 有効性評価に基づく胃がん検診ガイドライン 2014年版, 国立がん研究センターがん予防・検診研究センター, 2015.
6) Hamashima C, et al : A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One 8 : e79088, 2013.
7) Jun JK, et al : Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology 152 : 1319-1328.e7, 2017.
8) Kawai T, et al : Comparison of the effects on cardiopulmonary function of ultrathin transnasal versus normal diameter transoral esophagogastroduodenoscopy in Japan. Hepatogastroenterology 54 : 770-774, 2007.
9) Yagi J, et al : A prospective randomized comparative study on the safety and tolerability of transnasal esophagogastroduodenoscopy. Endoscopy 37 : 1226-1231, 2005.
10) IARC Helicobacter pylori Working Group : Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer, IARC Working Group Report, volume 8, IARC, Lyon, 2014.
P.19 掲載の参考文献
1) Sung H, et al : Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 : 209-249, 2021.
2) Parkin DM, et al : Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 : 827-841, 1999.
3) Pisani P, et al : Erratum : Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999). Int J Cancer 83 : 870-873, 1999.
4) Sekiguchi M, et al : Epidemiological Trends and Future Perspectives of Gastric Cancer in Eastern Asia. Digestion 103 : 22-28, 2022.
5) GBD 2017 Stomach cancer collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017 : a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 5 : 42-54, 2020.
6) Allemani C, et al : Global surveillance of trends in cancer survival 2000-14 (CONCORD-3) : analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 populationbased registries in 71 countries. Lancet 391 : 1023-1075, 2018.
7) Jun JK, et al : Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology 152 : 1319-1328.e7, 2017.
8) Hamashima C, et al : Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol 48 : 673-683, 2018.
9) Sekiguchi M, et al : Risk stratification and predictive risk-scoring model for lymph node metastasis in early gastric cancer. J Gastroenterol 51 : 961-970, 2016.
10) 関口正宇, ほか : 高齢早期胃癌患者に対するESD新規適応規準設定に向けて-「早期胃癌に対する内視鏡的粘膜下層剥離術の高齢者適応に関する第III相単群検証的試験 (JCOG1902) 」. 胃と腸 55 : 1517-1523, 2020.
11) Kakiuchi T, et al : A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture : a preliminary report. J Gastroenterol 54 : 699-707, 2019.
12) Kusano C, et al : The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer 20 : 16-19, 2017.
P.27 掲載の参考文献
1) Shikata K, et al : A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population : the Hisayama study. Int J Cancer 119 : 196-201, 2006.
4) Ono S, et al : Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 86 : 59-65, 2012.
5) 井上和彦, ほか : 胃癌発生の背景粘膜-人間ドックにおける内視鏡検査からの検討. 胃と腸 44 : 1367-1373, 2009.
7) Nishibayashi H, et al : Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. J Gastroenterol Hepatol 18 : 1384-1391, 2003.
8) Kamada T, et al : Nodular gastritis and gastric cancer. Dig Endosc 18 : 79-83, 2006.
10) Uemura N, et al : Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6 : 639-642, 1997.
12) Ford AC, et al : Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals : systematic review and meta-analysis of randomised controlled trials. BMJ 348 : g3174, 2014.
13) Nishikawa I, et al : Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open 2 : 80-86, 2018.
14) 胃炎の京都分類 [改訂第2版] (春間賢監), 日本メディカルセンター, 2018.
P.31 掲載の参考文献
1) 柳井秀雄, 今井章介 : EBウイルスと慢性炎症と腫瘍, EBウイルス関連胃癌 (柳井秀雄, ほか編), p21-27, 診断と治療社, 2016.
4) Yanai H, et al : Endoscopic and pathologic features of Epstein-Barr virus-associated gastric carcinoma. Gastrointest Endosc 45 : 236-242, 1997.
5) Yanai H, et al : Endoscopic and pathologic motifs for the clinical diagnosis of Epstein-Barr virus-associated gastric cancer. DEN Open 1 : e7, 2021. (DOI : 10.1002/deo2.7)
7) Kitayama Y, et al : Epstein-Barr virus-related gastric pseudolymphoma in infectious mononucleosis. Gastrointest Endosc 52 : 290-291, 2000.
8) Hirano A, et al : Evaluation of epstein-barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay. Int J Gastrointest Cancer 34 : 87-94, 2003.
9) Kartika AV, et al : Application of biopsy samples used for Helicobacter pylori urease test to predict Epstein-Barr virus-associated cancer. Microorganisms 8 : 923, 2020. (doi : 10.3390/microorganisms8060923)
10) Imai S, et al : Gastric carcinoma : monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 91 : 9131-9135, 1994.
11) Imai S, et al : Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72 : 4371-4378, 1998.
12) Iwakiri D, et al : Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 63 : 7062-7067, 2003.
13) Saju P, et al : Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. Nat Microbiol 1 : 16026, 2016.
14) Fukayama M, et al : Gastritis-Infection-Cancer sequence of Epstein-Barr virus-Associated Gastric Cancer. Adv Exp Med Biol 1045 : 437-457, 2018. (DOI : 10.1007/978-981-10-7230-7_20.)
15) Okabe A, et al : Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma. Nat Genet 52 : 919-930, 2020. (DOI : 10.1038/s41588-020-0665-7)
P.39 掲載の参考文献
1) World Cancer Research Fund/American Institute for Cancer Research : Food, Nutrition, Physical Activity, and the Prevention of Cancer : a Global Perspective, AICR, Washington DC, 2007.
2) World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer : a Global Perspective, The Third Expert Report, Continuous Update Project, 2018.
3) International Agency for Research on Cancer : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol.100E, IARC, Lyon, 2012.
4) Shimazu T, et al : Alcohol drinking and gastric cancer risk : an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 38 : 8-25, 2008.
6) Masaoka H, et al : Alcohol Drinking and Bladder Cancer Risk From a Pooled Analysis of Ten Cohort Studies in Japan. J Epidemiol 30 : 309-313, 2020.
7) Hidaka A, et al : Genetic polymorphisms of ADH1B, ADH1C and ALDH2, alcohol consumption, and the risk of gastric cancer : the Japan Public Health Center-based prospective study. Carcinogenesis 36 : 223-231, 2015.
9) Hirabayashi M, et al : Effect of body-mass index on the risk of gastric cancer : A population-based cohort study in A Japanese population. Cancer Epidemiol 63 : 101622, 2019.
10) Shimazu T, et al : Association of vegetable and fruit intake with gastric cancer risk among Japanese : a pooled analysis of four cohort studies. Ann Oncol 25 : 1228-1233, 2014.
P.45 掲載の参考文献
2) Lauren P : The two histological main types of gastric carcinoma : Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64 : 31-49, 1965.
3) Caldas C, et al : Familial gastric cancer : overview and guidelines for management. J Med Genet 36 : 873-880, 1999.
4) Boland CR, Yurgelun MB : Historical Perspective on Familial Gastric Cancer. Cell Mol Gastroenterol Hepatol 3 : 192-200, 2017.
6) Majewski IJ, et al : An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 229 : 621-629, 2013.
8) Blair VR, et al : Hereditary diffuse gastric cancer : updated clinical practice guidelines. Lancet Oncol 21 : e386-e397, 2020.
9) Lowstuter K, et al : Unexpected CDH1 mutations identified on multigene panels pose clinical management challenges. JCO Precision Oncology, 2017. (DOI : 10.1200/PO.16.00021)
10) Sugimoto S, et al : Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene. Gastric Cancer 17 : 745-749, 2014.
11) Li J, et al : Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet 98 : 830-842, 2016.
12) 遺伝性大腸癌診療ガイドライン 2020年版 (大腸癌研究会編), 金原出版, 2020.
13) 松本主之, ほか : 小児・成人のための若年性ポリポーシス症候群診療ガイドライン (2020年版). 遺伝性腫瘍 20 : 79-92, 2020.
14) McGarrity TJ, et al : Peutz-Jeghers syndrome. GeneReviews [Internet]. University of Washington, Seattle, 1993-2021. [https://www.ncbi.nlm.nih.gov/books/NBK1266/]
15) Idos G, Valle L : Lynch syndrome. GeneReviews [Internet]. University of Washington, Seattle, 1993-2021. [https://www.ncbi.nlm.nih.gov/books/NBK1211/]
P.52 掲載の参考文献
1) 三隅厚信, 瀬戸泰之 : 食道胃接合部をめぐる歴史. 消化器内科 3 : 6-13, 2021.
2) 胃癌取扱い規約 [第15版] (日本胃癌学会編), 金原出版, 2017.
3) 食道癌取扱い規約 [第11版] (日本食道学会編), 金原出版, 2015.
7) Horii T, et al : Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan : evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 46 : 710-719, 2011.
8) 小池智幸, ほか : 食道胃接合部癌. 別冊日本臨牀消化管症候群 I, p288-295, 日本臨牀社, 2019.
9) Sung H, et al : Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 : 209-249, 2021.
10) 中谷泰樹, ほか : 胃癌 (Helicobacter pylori関連の一般型). 別冊日本臨牀消化管症候群 I, p222-227, 日本臨牀社, 2019.
11) Matsueda K, et al : Clinical characteristics and associated factors of Japanese patients with adenocarcinoma of the esophagogastric junction : a multicenter clinicoepidemiological study. Dis Esophagus 30 : 1-6, 2017.
12) 胃食道逆流症 (GERD) 診療ガイドライン 2021 [改訂第3版] (日本消化器病学会編), 南江堂, 2021.
13) Inomata Y, et al : Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol 101 : 926-933, 2006.
14) Iijima K, et al : Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122 : 1248-1257, 2002.

II 胃癌の発癌機序

P.60 掲載の参考文献
1) 藤城光弘 : 胃癌, 腺腫. 専門医のための消化器病学 (木下芳一, ほか編), p123-131, 医学書院, 2021.
2) 津川仁 : Helicobacter pylori傷害機序の新知見. Helicobacter Research 24 : 25-37, 2020.
3) 鈴木秀和, 森英毅 : ピロリ菌除菌後の胃がん (除菌後胃がん). 癌と化学療法 45 : 1123-1127, 2018.
4) 寺村茉利, ほか : 胃癌の発癌機序-ゲノム異常・DNAメチル化を介した胃癌発癌機序の多様性-. 消化器内視鏡32 : 12-17, 2020.
5) 渡二郎, ほか : 胃粘膜の遺伝子異常からみた胃癌リスク. 日本ヘリコバクター学会誌 20 : 24-27, 2018.
6) 牛島俊和, 露木翔 : Helicobacter pylori現感染・除菌後胃がんの分子生物学的特徴. Helicobacter Research 24 : 168-175, 2020.
7) Masuda K, et al : Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy. J Gastroenterol 54 : 907-915, 2019.
8) 河内洋 : Helicobacter pylori現感染・除菌後胃がんの病理学的特徴. Helicobacter Research 24 : 162-169, 2020.
9) 牛久哲男, ほか. 胃癌の病理-背景粘膜に応じた胃癌の病理学的多様性-. 消化器内視鏡 32 : 18-24, 2020.
10) 津金昌一郎 : 本邦における胃がんの未来予想図と今後の胃がん検診のあり方. 消化器内視鏡 31 : 1742-1748, 2019.
11) 加藤元嗣, ほか : Helicobacter pyloriと胃悪性疾患とのかかわり. Helicobacter Research 24 : 41-46, 2020.
12) 渡邉俊雄, 藤原靖弘 : Helicobacter pylori除菌による胃がん抑制の新知見. Helicobacter Research 24 : 47-51, 2020.
13) Rokkas T, et al : Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection : A Network Meta-analysis. Gastroenterology 161 : 495-507.e4, 2021.
14) Hirata Y, et al : Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection : A prospective single-arm study. Helicobacter 25 : e12719, 2020.
15) 水野元夫 : Helicobacter pylori除菌で, 胃癌は撲滅できる. 倉敷中央病院年報 79 : 1-11, 2016.
P.67 掲載の参考文献
5) Hayashi T, et al : Differential Mechanisms for SHP2 Binding and Activation Are Exploited by Geographically Distinct Helicobacter pylori CagA Oncoproteins. Cell Rep 20 : 2876-2890, 2017.
6) Saadat I, et al : Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 447 : 330-333, 2007.
7) Wodarz A, Nathke I : Cell polarity in development and cancer. Nat Cell Biol 9 : 1016-1024, 2007.
8) Saito Y, et al : Conversion of Helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21. J Exp Med 207 : 2157-2174, 2010.
10) Kidane D : Molecular mechanisms of H. pylori-induced DNA double-strand breaks. Int J Mol Sci 19 : 2891, 2018.
11) Imai S, et al : Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis. Cell Host Microbe 29 : 941-958.e10, 2021.
12) Lord CJ, Ashworth A : BRCAness revisited. Nat Rev Cancer 16 : 110-120, 2016.
13) Alexandrov LB, et al : A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun 6 : 8683, 2015.
14) Shimizu T, et al : Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology 147 : 407-417.e3, 2014.
15) Fan F, et al : Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention : A systematic review and meta-analysis. J Eval Clin Pract 26 : 308-315, 2020.
P.72 掲載の参考文献
1) Schlemper RJ, et al : Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 349 : 1725-1729, 1997.
2) WHO Classification of Tumours Editorial Board : WHO Classification of Tumours, 5th ed, vol.1, Digestive System Tumours, IARC, Lyon, 2019.
3) 胃癌取扱い規約 [第15版] (日本胃癌学会編), 金原出版, 2017.
4) 河内洋, ほか : スキルス胃癌の病理診断. 胃と腸 55 : 770-777, 2020.
5) 滝澤登一郎, ほか : Linitis plastica型胃癌の成立と癌性リンパ管症. 胃と腸 27 : 591-598, 1992.
6) 河内洋, ほか : 胃乳頭状腺癌の悪性度と病理診断. 病理と臨床 23 : 960-965, 2005.
7) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
8) 河端美則, ほか : 癌性リンパ管症の病理-進展形式を中心に. 肺癌 22 : 27-34, 1982.
9) 佐藤隆, ほか : 肺の癌性リンパ管症の臨床病理学的検討-その発生と進展様式-. 日本胸部疾患学会雑誌 26 : 1243-1248, 1988.
10) Janower ML, Blennerhassett JB : Lymphangitic spread of metastatic cancer to the lung. A radiologicpathologic classification. Radiology 101 : 267-273, 1971.
11) Sawabe M, et al : Diffuse intrasinusoidal metastasis of gastric carcinoma to the liver leading to fulminant hepatic failure. A case report. Cancer 65 : 169-173, 1990.
13) 岡千紘, ほか : 生前にPulmonary tumor thrombotic microangiopathyと診断でき剖検にて胃の早期癌が原発と判明した一例. 病理と臨床 38 : 949-954, 2020.
14) 神谷知至, ほか : 胃癌の転移による播種性骨髄癌症の臨床病理学的検討. 癌の臨床 31 : 819-826, 1985.
15) 菊池由宣, ほか : 胃癌骨髄癌腫症本邦報告例および自験例の検討. 東邦医学会雑誌 57 : 127-136, 2010.
16) 坪川孝志, ほか (編) : 最新脳神経外科学, p593-602, 朝倉書店, 1996.
17) 桑原道郎, ほか : 胃癌による髄膜癌腫症に対し腰椎髄液腔-腹腔短絡手術が緩和医療に寄与した1例. 日本消化器外科学会雑誌 42 : 1557-1561, 2009.
18) 岡澤美佳, ほか : Krukenberg腫瘍を契機として発見された胃微小印環細胞癌の1例. 産婦人科の進歩 60 : 219-223, 2008.
19) Dohmen K, et al : Retroperitoneal fibrosis associated with scirrhous gastric cancer. Gastroenterol Jpn 28 : 699-705, 1993.

III 胃癌取扱い規約・胃癌治療ガイドライン

P.82 掲載の参考文献
1) TNM Classification of Malignant Tumours, 8th ed. (ed by Brierley JD, et al), Wiley Blackwell, 2017.
2) AJCC Cancer Staging Manual, 8th ed. (ed by Amin MB, et al), Springer-Verlag, New York, 2017.
3) Kajitani T : The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 11 : 127-139, 1981.
4) Japanese Gastric Cancer Association : Japanese classification of gastric carcinoma : 3rd English edition. Gastric Cancer 14 : 101-112, 2011.
5) 胃癌取扱い規約 第15版 (日本胃癌学会編), 金原出版, 2017.
7) Siewert Stein HJ : Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 : 1457-1459, 1998.
P.88 掲載の参考文献
1) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
3) Sasako M, et al : D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 : 453-462, 2008.
5) Minds診療ガイドライン作成マニュアル 2020 ver.3.0. (Minds診療ガイドライン作成マニュアル編集委員会編), 2021. [https://minds.jcqhc.or.jp/s/manual_2020_3_0]
6) Yu J, et al : Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer : The CLASS-01 Randomized Clinical Trial. JAMA 321 : 1983-1992, 2019.
7) Hyung WJ, et al : Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer : The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol 38 : 3304-3313, 2020.
8) Baiocchi GL, et al : Follow-up after gastrectomy for cancer : results of an international web round table. World J Gastroenterol 20 : 11966-11971, 2014.
P.94 掲載の参考文献
1) Hasuike N, et al : A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a) : the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer 21 : 114-123, 2018.
2) Takizawa K, et al : A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer : Japan Clinical Oncology Group study (JCOG1009/1010). Gastric Cancer 24 : 479-491, 2021.
3) Gotoda T, et al : Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg 88 : 444-449, 2001.
6) Suzuki H, et al : Short-term outcomes of multicenter prospective cohort study of gastric endoscopic resection : 'Real-world evidence' in Japan. Dig Endosc 31 : 30-39, 2019.
7) Takizawa K, et al : Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection--an analysis of risk factors. Endoscopy 40 : 179-183, 2008.
8) Uedo N, et al : Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer : a prospective randomized controlled trial. Am J Gastroenterol 102 : 1610-1616, 2007.
9) Yang Z, et al : Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection : a meta-analysis of randomized trials. Digestion 84 : 315-320, 2011.
10) Mochizuki S, et al : Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial) : a multicentre prospective randomised controlled non-inferiority trial. Gut 64 : 397-405, 2015.
11) Nishizawa T, et al : Second-look endoscopy after endoscopic submucosal dissection for gastric neoplasms. Dig Endosc 27 : 279-284, 2015.

IV 胃癌の検査・診断

P.100 掲載の参考文献
1) 豊泉博史, 田尻久雄 : 胃癌の検査・診断 : 概論. 日本臨牀 72 (増刊 1) : 251-256, 2014.
2) 国立がん研究センターがん情報サービス : がん統計. 厚生労働省人口動態統計, 2020.
3) Ekstrom AM, et al : Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121 : 784-791, 2001.
5) Kawai S, et al : Lifetime incidence risk for gastric cancer in the Helicobacter pylori-infected and uninfected population in Japan : A Monte Carlo simulation study. Int J Cancer 150 : 18-27, 2022.
6) Sugano K : Effect of Helicobacter pylori eradication on the incidence of gastric cancer : a systematic review and meta-analysis. Gastric Cancer 22 : 435-445, 2019.
7) Kato M, et al : Self-study of the non-extension sign in an e-learning program improves diagnostic accuracy of invasion depth of early gastric cancer. Endosc Int Open 7 : E871-E882, 2019.
8) Hamashima C, et al : Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci 106 : 1744-1749, 2015.
9) Hirasawa T, et al : Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. Gastric Cancer 21 : 653-660, 2018.
10) Horiguchi N, et al : In vivo diagnosis of early-stage gastric cancer found after Helicobacter pylori eradication using probe-based confocal laser endomicroscopy. Dig Endosc 30 : 219-227, 2018.
11) Akin EA, et al : Clinical impact of FDG PET/CT in alimentary tract malignancies : an updated review. Abdom Radiol (NY) 45 : 1018-1035, 2020.
12) Mukai K, et al : Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 9 : 192-196, 2006.
13) Kim JH, et al : Evaluation of recurrence in gastric carcinoma : Comparison of contrast-enhanced computed tomography and positron emission tomography/computed tomography. World J Gastroenterol 23 : 6448-6456, 2017.
14) Handa O, Naito Y : Chapter 14 : Prevention Strategy for Gastric Cancer. In : Gastric Cancer-With Special Focus on Studies from Japan (ed by Shiotani A), p193-201, Springer, Singapore, 2019.
P.107 掲載の参考文献
1) 久道茂 : がん検診の有効性評価に関する研究班 (主任研究者 : 久道茂) 報告書, 日本公衆衛生協会, 1998.
2) 祖父江友孝 : 有効性評価に基づく胃がん検診ガイドライン (主任研究者 : 祖父江友孝), 平成17年度厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究班」報告. 2006.
3) Hamashima C, et al : A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One 8 : e79088, 2013.
4) Jun JK, et al : Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 152 : 1319-1328.e7, 2017.
5) 有効性評価に基づく胃がん検診ガイドライン 2014年度版 (国立がん研究センターがん予防・検診研究センター), 2015. [http://canscreen.ncc.go.jp/guideline/iganguide2014_150421.pdf]
6) 新・胃X線撮影法ガイドライン 改訂版 (日本消化器がん検診学会胃がん検診精度管理委員会編), 医学書院, 2011.
7) 渋谷大助, ほか : 胃X線検診のための読影判定区分 (委員会報告). 日本消化器がん検診学会雑誌 54 : 73-76, 2016.
8) 対策型検診のための胃内視鏡検診マニュアル (日本消化器がん検診学会対策型検診のための胃内視鏡検診マニュアル作成委員会編), 南江堂, 2017.
9) 井上和彦, ほか : 被験者に優しい健診内視鏡検査. 日本消化器内視鏡学会雑誌 52 : 274-277, 2010.
10) 八尾建史, ほか (日本消化器内視鏡学会早期胃癌の内視鏡診断ガイドライン委員会) : 早期胃癌の内視鏡診断ガイドライン. 日本消化器内視鏡学会雑誌 61 : 1283-1319, 2019.
11) 古田隆久, ほか : 消化器内視鏡関連の偶発症に関する第6回全国調査報告 2008年~2012年までの5年間. 日本消化器内視鏡学会雑誌 58 : 1466-1491, 2016.
12) 加藤元嗣, ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン直接経口抗凝固薬 (DOAC) を含めた抗凝固薬に関する追補 2017. 日本消化器内視鏡学会雑誌 59 : 1547-1558, 2017.
13) 胃炎の京都分類 [改訂第2版] (春間賢監), 日本メディカルセンター, 2018.
14) Inoue K : Stratification of gastric cancer risk by H.pylori infection. In : Helicobacter pylori (ed by Suzuki H, et al), p169-179, Springer, Tokyo, 2016.
15) Terasawa T, et al : Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians : a systematic review and meta-analysis. PLoS One 9 : e109783, 2014.
P.113 掲載の参考文献
1) 胃癌治療ガイドライン 第6版 (日本胃癌学会編), 金原出版, 2021.
2) 小野裕之 : 早期胃癌内視鏡治療と適応. 胃と腸 56 : 7-8, 2021.
3) 胃癌取扱い規約第15版 (日本胃癌学会編), 金原出版, 2017.
4) 中原慶太, ほか : 陥凹型胃癌に対するX線的深達度診断プロセス. 胃と腸 41 : 1327-1343, 2006.
5) 海崎泰治, ほか : 病理からみた早期胃癌の深達度診断. 胃と腸 50 : 583-591, 2015.
6) 中島寛隆, 大倉康男 : 早期胃癌の組織型と肉眼像. 消化器内視鏡 26 : 1097-1105, 2014.
7) 藤崎順子, ほか : 通常観察時にSM浸潤を疑わせる内視鏡所見. 消化器内視鏡 23 : 849-857, 2011.
8) 八尾恒良, ほか : 胃の陥凹型SM癌の病理組織構築と対比した内視鏡所見-pSM2癌診断のための観察方法と診断限界. 胃と腸 43 : 1109-1125, 2008.
9) 宮岡正喜, ほか : 早期胃癌EMR/ESDの絶対適応病変を決定するための術前内視鏡診断と問題点-台状挙上所見を用いた通常色素内視鏡診断による早期胃癌の深達度診断. 胃と腸 56 : 17-30, 2021.
10) 浜田勉, ほか : これがBasic technique II 上部消化管A 診断通常内視鏡における早期胃癌の深達度診断の基本. 消化器内視鏡 17 : 1535-1540, 2005.
11) 丸山保彦, ほか : 通常・色素内視鏡による早期胃癌深達度診断-大きさ・肉眼型別検討を中心に. 胃と腸 49 : 35-46, 2014.
P.119 掲載の参考文献
1) Tajiri H, Niwa H : Proposal for a consensus terminology in endoscopy : how should different endoscopic imaging techniques be grouped and defined? Endoscopy 40 : 775-778, 2008.
2) Nagahama T, et al : Delineation of the extent of early gastric cancer by magnifying narrow-band imaging and chromoendoscopy : a multicenter randomized controlled trial. Endoscopy 50 : 566-576, 2018.
3) Kawahara Y, et al : Novel chromoendoscopic method using an acetic acid-indigocarmine mixture for diagnostic accuracy in delineating the margin of early gastric cancers. Dig Endosc 21 : 14-19, 2009.
5) Yagi K, et al : Green epithelium revealed by narrow-band imaging (NBI) : a feature for practical assessment of extent of gastric cancer after H. pylori eradication. Endosc Int Open 6 : E1289-E1295, 2018.
6) Muto M, et al : Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDAG). Dig Endosc 28 : 379-393, 2016.
7) Yoshida N, et al : Early gastric cancer detection in high-risk patients : a multicentre randomised controlled trial on the effect of second-generation narrow band imaging. Gut 70 : 67-75, 2021.
8) Dohi O, et al : Magnifying Blue Laser Imaging versus Magnifying Narrow-Band Imaging for the Diagnosis of Early Gastric Cancer : A Prospective, Multicenter, Comparative Study. Digestion 96 : 127-134, 2017.
9) Kimura-Tsuchiya R, et al : Magnifying Endoscopy with Blue Laser Imaging Improves the Microstructure Visualization in Early Gastric Cancer : Comparison of Magnifying Endoscopy with Narrow-Band Imaging. Gastroenterol Res Pract 2017 : 8303046, 2017.
10) Yasuda T, et al : Benefits of linked color imaging for recognition of early differentiated-type gastric cancer : in comparison with indigo carmine contrast method and blue laser imaging. Surg Endosc 35 : 2750-2758, 2021.
11) Dohi O, et al : Blue laser imaging-bright improves the real-time detection rate of early gastric cancer : a randomized controlled study. Gastrointest Endosc 89 : 47-57, 2019.
12) Ono S, et al : Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial. Ann Intern Med 174 : 18-24, 2021.
13) Majima A, et al : Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori. Gastrointest Endosc 90 : 763-769, 2019.
15) 八木一芳, ほか : 色調逆転現象と除菌後発見胃癌. 消化器内視鏡 30 : 83-84, 2018.
P.126 掲載の参考文献
3) Kato M, et al : Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer : a multicenter retrospective cohort study by Osaka University ESD study group. Gut 62 : 1425-1432, 2013.
4) Aoi T, et al : Risk of subsequent development of gastric cancer in patients with previous gastric epithelial neoplasia. Gut 55 : 588-589, 2006.
5) Mori G, et al : Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication : results of a large-scale, multicenter cohort study in Japan. Gastric Cancer 19 : 911-918, 2016.
7) Yoon SB, et al : Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors : a meta-analysis. Helicobacter 19 : 243-248, 2014.
8) 小野裕之, ほか : 胃癌に対するESD/EMRガイドライン (第2版). Gastroenterol Endosc 62 : 275-290, 2020.
9) 赤松拓司, ほか : 胃ESD 後のサーベイランス. 消化器内視鏡 30 : 463-470, 2018.
10) 大澤博之, ほか : 注目の画像強調内視鏡を使いこなすLCI (Linked Color Imaging) -その原理と臨床応用. 消化器内視鏡 33 : 1232-1239, 2021.
11) Yoshifuku Y, et al : Evaluation of the visibility of early gastric cancer using linked color imaging and blue laser imaging. BMC Gastroenterol 17 : 150, 2017.
12) Kanzaki H, et al : Linked color imaging (LCI), a novel image-enhanced endoscopy technology, emphasizes the color of early gastric cancer. Endosc Int Open 5 : E1005-E1013, 2017.
13) Ono S, et al : Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial. Ann Intern Med 174 : 18-24, 2021.
14) Yamaoka M, et al : Detection of early stage gastric cancers in screening laser endoscopy using linked color imaging for patients with atrophic gastritis. J Gastroenterol Hepatol 36 : 1642-1648, 2021.
15) Maehata Y, et al : Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 75 : 39-46, 2012.
16) Choi J, et al : Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 12 : 793-800.e1, 2014.
18) Nakajima T, et al : Metachronous gastric cancers after endoscopic resection : how effective is annual endoscopic surveillance? Gastric Cancer 9 : 93-98, 2006.
19) Abe S, et al : Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy 47 : 1113-1118, 2015.
20) 今枝博之, ほか : 最新の内視鏡光源・プロセッサー各社製品の紹介と使用上の注意. 消化器内視鏡 33 : 1210-1221, 2021.
21) Ishikawa T, et al : Efficacy of Texture and Color Enhancement Imaging in visualizing gastric mucosal atrophy and gastric neoplasms. Sci Rep 11 : 6910, 2021.
P.133 掲載の参考文献
1) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
2) 依光展和, ほか : 切除標本の取り扱いと正しい病理依頼法. 消化器内視鏡 26 : 1223-1232, 2014.
3) 高橋亜紀子, ほか : 臨床医が知っておくべきEMR・ESD切除標本の取り扱い. 消化器内視鏡 25 : 1428 -1432, 2013.
4) 高橋亜紀子, 小山恒男 : 胃切除標本の取り扱い. 食道・胃ESDの基本手技 (小山恒男編), p201-204, メジカルビュー社, 2007.
5) 胃癌取扱い規約 [第15版] (日本胃癌学会編), 金原出版, 2017.
6) 小野裕之, ほか : 胃癌に対するESD/EMRガイドライン (第2版). Gastroenterol Endosc 62 : 273-290, 2020.
P.138 掲載の参考文献
4) Camargo MC, et al : Improved survival of gastric cancer with tumour Epstein-Barr virus positivity : an international pooled analysis. Gut 63 : 236-243, 2014.
5) Tsuji Y, et al : Risk for lymph node metastasis in Epstein-Barr virus-associated gastric carcinoma with submucosal invasion. Dig Endosc 33 : 592-597, 2021.
6) Saiki Y, et al : Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma : massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest 75 : 67-76, 1996.
7) Song HJ, et al : Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139 : 84-92.e2, 2010.
11) Abe H, et al : ARID1A expression loss in gastric cancer : pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 461 : 367-377, 2012.
12) Abe H, et al : Virus-host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma : Potential roles of lost ARID1A expression in its early stage. PLoS One 16 : e0256440, 2021.
13) Saito R, et al : Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer : the prognostic implications. Mod Pathol 30 : 427-439, 2017.
15) Kim ST, et al : Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24 : 1449-1458, 2018.

V 胃癌の治療

P.145 掲載の参考文献
1) Inoue M : Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer 20 : 3-7, 2017.
2) Olch PD : Johann von Mikulicz-Radecki. Ann Surg 152 : 923-926, 1960.
3) 三宅速, ほか : 胃癌. 克誠堂, 1928.
4) 井上與惣一 : 胃, 十二指腸, 膵臟竝ビニ横隔膜ノ淋巴管系統. 解剖學雑誌 9 : 35-117, 1936.
5) 梶谷環 : リンパ系統の徹底的郭清術. 日本外科学会雑誌 51 : 464, 1953.
6) Japanese Gastric Cancer Association Registration Committee ; Maruyama K, et al : Gastric cancer treated in 1991 in Japan : data analysis of nationwide registry. Gastric Cancer 9 : 51-66, 2006.
8) Sasako M, et al : New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 82 : 346-351, 1995.
9) Sasako M, et al : D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 : 453-462, 2008.
11) Groves EW : On the radical operation for cancer of the pylorus : With especial reference to the advantages of the two-stage operation and to the question of the removal of the associated lymphatics. Br Med J 1 : 366-370, 1910.
12) Brunschwig A : Pancreato-total gastrectomy and splenectomy for advanced carcinoma of the stomach. Cancer 1 : 427-430, 1948.
13) McNeer G, James A : Resection of stomach and adjacent organs in continuity for advanced cancer. Cancer 1 : 449-454, 1948.
14) McNeer G, et al : A more thorough operation for gastric cancer ; anatomical basis and description of technique. Cancer 4 : 957-967, 1951.
15) Lawrence W Jr, McNeer G : An analysis of the role of radical surgery for gastric cancer. Surg Gynecol Obstet 111 : 691-696, 1960.
16) Allum WH, et al : Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1 : 571-574, 1989.
17) Cuschieri A, et al : Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer : preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347 : 995-999, 1996.
18) Degiuli M, et al : Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 101 : 23-31, 2014.
21) Network NCC NCCN Guidelines Version 5.2021, Gastric Cancer, 2021.
P.151 掲載の参考文献
1) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
2) Kitagawa Y, et al : Sentinel node mapping for gastric cancer : A prospective multicenter trial in Japan. J Clin Oncol 31 : 3704-3710, 2013.
3) Fukagawa T, et al : A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer 21 : 68-73, 2018.
4) 日本内視鏡外科学会学術委員会 : 内視鏡外科手術に関するアンケート調査-第15回集計結果報告-. 日本内視鏡外科学会, 2021.
5) Katai H, et al : Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912) : a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5 : 142-151, 2020.
6) Katai H, et al : Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer : Japan Clinical Oncology Group study JCOG1401. Gastric Cancer 22 : 999-1008, 2019.
8) Hiki N, et al : Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. Gastric Cancer 21 : 162-170, 2018.
9) Etoh T, et al : Morbidity and mortality from a propensity score-matched, prospective cohort study of laparoscopic versus open total gastrectomy for gastric cancer : data from a nationwide web-based database. Surg Endosc 32 : 2766-2773, 2018.
10) Yoshida K, et al : Surgical outcomes of laparoscopic distal gastrectomy compared to open distal gastrectomy : A retrospective cohort study based on a nationwide registry database in Japan. Ann Gastroenterol Surg 2 : 55-64, 2018.
11) Kodera Y, et al : Introducing laparoscopic total gastrectomy for gastric cancer in general practice : a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer 22 : 202-213, 2019.
12) Takiguchi N, et al : Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45) : a nationwide multiinstitutional study. Gastric Cancer 18 : 407-416, 2015.
13) Suda K, et al : Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage : a retrospective cohort study using a nationwide registry database in Japan. Gastric Cancer, 2021. (DOI : 10.1007/s10120-021-01257-7)
P.156 掲載の参考文献
1) 常岡健二, 内田隆也 : われわれの考案した内視鏡下の胃ポリープ切断採取法-ポリープ切断器及び採取器について-. 日本消化器内視鏡学会雑誌 11 : 174-184, 1969.
3) 平尾雅紀, ほか : 胃の腫瘍性病変に対する内視鏡的切除法. 日本消化器内視鏡学会雑誌 25 : 1942-1953, 1983.
4) 多田正弘, ほか : Strip-off biopsyの開発. 日本消化器内視鏡学会雑誌 26 : 833-839, 1984.
5) Inoue H, et al : Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 39 : 58-62, 1993.
6) Akiyama M, et al : Endoscopic mucosal resection of gastric neoplasms using a ligating device. Gastrointest Endosc 45 : 182-186, 1997.
8) 細川浩一, 吉田茂昭 : 早期胃癌の内視鏡的胃粘膜切除術. 癌と化学療法 25 : 476-483, 1998.
9) Watanabe K, et al : Clinical outcomes of EMR for gastric tumors : historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. Gastrointest Endosc 63 : 776-782, 2006.
11) Park YM, et al : The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer : a systematic review and metaanalysis. Surg Endosc 25 : 2666-2677, 2011.
12) Minami S, et al : Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery (with video). Gastrointest Endosc 63 : 596-601, 2006.
13) Ono H, et al : Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 11 : 47-52, 2008.
15) Yoshida M, et al : Conventional versus traction-assisted endoscopic submucosal dissection for gastric neoplasms : a multicenter, randomized controlled trial (with video). Gastrointest Endosc 87 : 1231-1240, 2018.
16) 胃癌治療ガイドライン [第1版] (日本胃癌学会編), 金原出版, 2001.
17) 胃癌治療ガイドライン 2014年5月改訂 [第4版] (日本胃癌学会編), 金原出版, 2014.
18) Hasuike N, et al : A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a) : the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer 21 : 114-123, 2018.
19) 胃癌治療ガイドライン 2018年1月改訂 [第5版] (日本胃癌学会編), 金原出版, 2018.
20) Takizawa K, et al : A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer : Japan Clinical Oncology Group study (JCOG1009/1010). Gastric Cancer 24 : 479-491, 2021.
21) 胃癌治療ガイドライン 2021年7月改訂 [第6版] (日本胃癌学会編), 金原出版, 2021.
25) Inoue H, et al : Endoscopic mucosal resection, endoscopic submucosal dissection, and beyond : full-layer resection for gastric cancer with nonexposure technique (CLEAN-NET). Surg Oncol Clin N Am 21 : 129-140, 2012.
P.161 掲載の参考文献
1) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
2) 胃癌取扱い規約 [第15版] (日本胃癌学会編), 金原出版, 2017.
3) 胃癌治療ガイドライン [第5版] (日本胃癌学会編), 金原出版, 2018.
4) Oka S, et al : Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 64 : 877-883, 2006.
5) Tanabe S, et al : Long-term outcomes of endoscopic submucosal dissection for early gastric cancer : a retrospective comparison with conventional endoscopic resection in a single center. Gastric Cancer 17 : 130-136, 2014.
7) Inoue H, et al : Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 39 : 58-62, 1993.
8) Hirao M, et al : Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 34 : 264-269, 1988.
9) 細川浩一, 吉田茂昭 : 早期胃癌の内視鏡的胃粘膜切除術. 癌と化学療法 25 : 476-483, 1998.
11) Bourke MJ, et al : Endoscopic submucosal dissection : Indications and application in Western endoscopy practice. Gastroenterology 154 : 1887-1900, 2018.
12) Mochizuki S, et al : Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial) : a multicentre prospective randomised controlled non-inferiority trial. Gut 64 : 397-405, 2015.
14) Yoshida M, et al : Conventional versus traction-assisted endoscopic submucosal dissection for gastric neoplasms : a multicenter, randomized controlled trial (with video). Gastrointest Endosc 87 : 1231-1240, 2018.
16) Esaki M, et al : Age Affects Clinical Management after Noncurative Endoscopic Submucosal Dissection for Early Gastric Cancer. Dig Dis 37 : 423-433, 2019.
P.167 掲載の参考文献
1) Suzuki H, et al : Short-term outcomes of multicenter prospective cohort study of gastric endoscopic resection : 'Real-world evidence' in Japan. Dig Endosc 31 : 30-39, 2019.
2) Tajiri H, Kitano S : Complications associated with endoscopic mucosal resection : definition of bleeding that can be viewed as accidental. Dig Endosc 16 : S134-S136, 2004.
3) Oda I, et al : Endoscopic submucosal dissection for early gastric cancer : Technical feasibility, operation time and complications from a large consecutive series. Dig Endosc 17 : 54-58, 2005.
4) Goto O, et al : A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary : a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc 71 : 241-248, 2010.
5) Libanio D, et al : Risk factors for bleeding after gastric endoscopic submucosal dissection : a systematic review and meta-analysis. Gastrointest Endosc 84 : 572-586, 2016.
6) Hatta W, et al : Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer : BEST-J score. Gut 70 : 476-484, 2021.
7) Dong J, et al : Effects of antithrombotic therapy on bleeding after endoscopic submucosal dissection. Gastrointest Endosc 86 : 807-816, 2017.
8) Higashiyama M, et al : Risk factors for bleeding after endoscopic submucosal dissection of gastric epithelial neoplasm. Dig Endosc 23 : 290-295, 2011.
10) Uedo N, et al : Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer : a prospective randomized controlled trial. Am J Gastroenterol 102 : 1610-1616, 2007.
11) Yang Z, et al : Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection : a meta-analysis of randomized trials. Digestion 84 : 315-320, 2011.
12) Hamada K, et al : Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers : a prospective randomized phase II study. J Gastroenterol 54 : 122-130, 2019.
13) Abe H, et al : Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment. J Gastroenterol 56 : 640-650, 2021.
14) Yang L, et al : Low-dose PPI to prevent bleeding after ESD : A multicenter randomized controlled study. Biomed Pharmacother 136 : 111251, 2021.
15) Lee SH, et al : Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers : a retrospective analysis and prospective validation study. Dig Dis Sci 57 : 429-434, 2012.
16) Xiong J, et al : Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer : a meta-analysis of randomized controlled trials. Medicine (Baltimore) 93 : e64, 2014.
17) Takizawa K, et al : Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection--an analysis of risk factors. Endoscopy 40 : 179-183, 2008.
18) Azumi M, et al : The search, coagulation, and clipping (SCC) method prevents delayed bleeding after gastric endoscopic submucosal dissection. Gastric Cancer 22 : 567-575, 2019.
19) Uedo N, et al : Endoscopic Doppler US for the prevention of ulcer bleeding after endoscopic submucosal dissection for early gastric cancer : a preliminary study (with video). Gastrointest Endosc 72 : 444-448, 2010.
20) Mochizuki S, et al : Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial) : a multicentre prospective randomised controlled non-inferiority trial. Gut 64 : 397-405, 2015.
21) Kamal F, et al : Role of routine second-look endoscopy in patients with acute peptic ulcer bleeding : meta-analysis of randomized controlled trials. Gastrointest Endosc 93 : 1228-1237.e5, 2021.
22) Shiotsuki K, et al : Endoloop closure following gastric endoscopic submucosal dissection to prevent delayed bleeding in patients receiving antithrombotic therapy. Scand J Gastroenterol 56 : 1117-1125, 2021.
23) Maekawa S, et al : Complete closure of artificial gastric ulcer after endoscopic submucosal dissection by combined use of a single over-the-scope clip and through-the-scope clips (with videos). Surg Endosc 29 : 500-504, 2015.
24) Goto O, et al : Endoscopic hand-suturing is feasible, safe, and may reduce bleeding risk after gastric endoscopic submucosal dissection : a multicenter pilot study (with video). Gastrointest Endosc 91 : 1195-1202, 2020.
25) Ego M, et al : Endoscopic Closure Utilizing Endoloop and Endoclips After Gastric Endoscopic Submucosal Dissection for Patients on Antithrombotic Therapy. Dig Dis Sci 66 : 2336-2344, 2021.
26) Fukuda H, et al : Polyglycolic Acid Felt Sealing Method for Prevention of Bleeding Related to Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents. Gastroenterol Res Pract 2016 : 1457357, 2016.
27) Kawata N, et al : Efficacy of polyglycolic acid sheets and fibrin glue for prevention of bleeding after gastric endoscopic submucosal dissection in patients under continued antithrombotic agents. Gastric Cancer 21 : 696-702, 2018.
28) Li F, et al : Polyglycolic acid sheets decrease post-endoscopic submucosal dissection bleeding in early gastric cancer : A systematic review and meta-analysis. J Dig Dis 21 : 437-444, 2020.
29) Kataoka Y, et al : Endoscopic tissue shielding to prevent bleeding after endoscopic submucosal dissection : a prospective multicenter randomized controlled trial. Endoscopy 51 : 619-627, 2019.
30) Barkun AN, et al : Management of Nonvariceal Upper Gastrointestinal Bleeding : Guideline Recommendations From the International Consensus Group. Ann Intern Med 171 : 805-822, 2019.
P.173 掲載の参考文献
1) 胃癌治療ガイドライン 医師用 [第6版] (日本胃癌学会編), 金原出版, 2021.
2) Kitano S, et al : Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 4 : 146-148, 1994.
3) Hiki N, et al : Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer : a multicenter phase II trial (JCOG0703). Gastric Cancer 21 : 155-161, 2018.
4) Katai H, et al : Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912) : a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5 : 142-151, 2020.
5) Kim HH, et al : Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer : The KLASS-01 Randomized Clinical Trial. JAMA Oncol 5 : 506-513, 2019.
6) Katai H, et al : Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer : Japan Clinical Oncology Group study JCOG1401. Gastric Cancer 22 : 999-1008, 2019.
7) Honda M, et al : Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage I Gastric Cancer : The LOC-1 Study. Ann Surg 264 : 214-222, 2016.
9) Hyung WJ, et al : Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer : The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol 38 : 3304-3313, 2020.
10) Yu J, et al : Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer : The CLASS-01 Randomized Clinical Trial. JAMA 321 : 1983-1992, 2019.
11) Kinoshita T, et al : Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage II/III Gastric Cancer : A Multicenter Cohort Study in Japan (LOC-A Study). Ann Surg 269 : 887-894, 2019.
12) Li Z, et al : Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer : A Randomized Clinical Trial. JAMA Surg 154 : 1093-1101, 2019.
13) Hashizume M, Sugimachi K : Robot-assisted gastric surgery. Surg Clin North Am 83 : 1429-1444, 2003.
14) Kumagai K, et al : Impact of anatomical position of the pancreas on postoperative complications and drain amylase concentrations after laparoscopic distal gastrectomy for gastric cancer. Surg Endosc 32 : 3846-3854, 2018.
15) Tsujiura M, et al : "Pancreas-Compressionless Gastrectomy" : A Novel Laparoscopic Approach for Suprapancreatic Lymph Node Dissection. Ann Surg Oncol 24 : 3331-3337, 2017.
16) Tokunaga M, et al : Late phase II study of robot-assisted gastrectomy with nodal dissection for clinical stage I gastric cancer. Surg Endosc 30 : 3362-3367, 2016.
17) Uyama I, et al : Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer : a multi-institutional prospective single-arm study. Gastric Cancer 22 : 377-385, 2019.
18) Kim HI, et al : Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg 263 : 103-109, 2016.
19) Kurokawa Y, et al : Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors : A Prospective Nationwide Multicenter Study. Ann Surg 274 : 120-127, 2021.
P.178 掲載の参考文献
1) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
P.183 掲載の参考文献
1) Marubashi S, et al : Surgical outcomes in gastroenterological surgery in Japan : Report of the National Clinical Database 2011-2019. Ann Gastroenterol Surg 5 : 639-658, 2021.
2) 日本内視鏡外科学会学術委員会 : 内視鏡外科手術に関するアンケート調査-第15回集計結果報告-, p43-46, 日本内視鏡外科学会, 2021.
3) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
4) Katai H, et al : Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer : Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer 20 : 699-708, 2017.
5) Kim W, et al : Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer : Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg 263 : 28-35, 2016.
7) Lee HJ, et al : Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg 270 : 983-991, 2019.
8) Hu Y, et al : Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer : A Randomized Controlled Trial. J Clin Oncol 34 : 1350-1357, 2016.
9) Yoshida K, et al : Surgical outcomes of laparoscopic distal gastrectomy compared to open distal gastrectomy : A retrospective cohort study based on a nationwide registry database in Japan. Ann Gastroenterol Surg 2 : 55-64, 2018.
10) Hiki N, et al : Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. Gastric Cancer 21 : 162-170, 2018.
12) Kanaya S, et al : Video : laparoscopy distinctive technique for suprapancreatic lymph node dissection : medial approach for laparoscopic gastric cancer surgery. Surg Endosc 25 : 3928-3929, 2011.
13) Shinohara H, et al : Tracing Dissectable Layers of Mesenteries Overcomes Embryologic Restrictions when Performing Infrapyloric Lymphadenectomy in Laparoscopic Gastric Cancer Surgery. J Am Coll Surg 220 : e81-87, 2015.
14) Katai H, et al : Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912) : a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5 : 142-151, 2020.
15) Kim HH, et al : Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer : The KLASS-01 Randomized Clinical Trial. JAMA Oncol 5 : 506-513, 2019.
16) Yu J, et al : Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer : The CLASS-01 Randomized Clinical Trial. JAMA 321 : 1983-1992, 2019.
17) Hyung WJ, et al : Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer : The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol 38 : 3304-3313, 2020.
P.189 掲載の参考文献
1) Katai H, et al : Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912) : a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5 : 142-151, 2020.
2) 胃癌治療ガイドライン 第6版 (日本胃癌学会編), 金原出版, 2021.
3) 槇哲夫, ほか : 胃良性疾患に対する胃切除法についての検討. 外科治療 13 : 505-512, 1965.
4) Fujita J, et al : Assessment of postoperative quality of life following pylorus-preserving gastrectomy and Billroth-I distal gastrectomy in gastric cancer patients : results of the nationwide postgastrectomy syndrome assessment study. Gastric Cancer 19 : 302-311, 2016.
5) Suh YS, et al : Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 259 : 485-493, 2014.
6) Kinami S, et al : The incidences of metachronous multiple gastric cancer after various types of gastrectomy : analysis of data from a nationwide Japanese survey. Gastric Cancer 24 : 22-30, 2021.
7) Takahashi R, et al : Risk factors and prognosis of gastric stasis, a crucial problem after laparoscopic pylorus-preserving gastrectomy for early middle-third gastric cancer. Gastric Cancer 23 : 707-715, 2020.
8) Morita S, et al : Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Surg 95 : 1131-1135, 2008.
9) Jiang X, et al : Postoperative outcomes and complications after laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Ann Surg 253 : 928-933, 2011.
10) Kiyokawa T, et al : Preserving infrapyloric vein reduces postoperative gastric stasis after laparoscopic pylorus-preserving gastrectomy. Langenbecks Arch Surg 402 : 49-56, 2017.
11) Park DJ, et al : Short-term outcomes of a multicentre randomized clinical trial comparing laparoscopic pylorus-preserving gastrectomy with laparoscopic distal gastrectomy for gastric cancer (the KLASS-04 trial). Br J Surg 108 : 1043-1049, 2021.
12) 森田信司 : 幽門保存胃切除による機能温存. 外科 81 : 430-433, 2019.
14) Kumagai K, et al : Totally laparoscopic pylorus-preserving gastrectomy for early gastric cancer in the middle stomach : technical report and surgical outcomes. Gastric Cancer 18 : 183-187, 2015.
15) Ohashi M, et al : A novel method of intracorporeal end-to-end gastrogastrostomy in laparoscopic pylorus-preserving gastrectomy for early gastric cancer, including a unique anastomotic technique : piercing the stomach with a linear stapler. Surg Endosc 32 : 4337-4343, 2018.
P.194 掲載の参考文献
1) Takiguchi N, et al : Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45) : a nationwide multi-institutional study. Gastric Cancer 18 : 407-416, 2015.
2) Ushimaru Y, et al : Clinical Outcomes of Gastric Cancer Patients Who Underwent Proximal or Total Gastrectomy : A Propensity Score-Matched Analysis. World J Surg 42 : 1477-1484, 2018.
3) 三宅速, ほか : 胃癌. p291-313, 克誠堂, 1928.
4) 太田恵一朗, ほか : 上部胃噴門癌の手術方針特に噴門側胃切除の適応基準について. 日本消化器外科学会雑誌 20 : 956-960, 1987.
6) Katai H, et al : Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer : Japan Clinical Oncology Group study JCOG1401. Gastric Cancer 22 : 999-1008, 2019.
7) Katai H, et al : Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912) : a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5 : 142-151, 2020.
9) Yura M, et al : Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. Gastric Cancer 22 : 1029-1035, 2019.
10) 梶谷鐶, ほか : 胃全摘並びに噴門側胃切除術式の検討. 日本外科学会雑誌 66 : 1285-1286, 1965.
11) 上川康明, ほか : 噴門側胃切除後の食道胃吻合法における工夫-徹底した逆流防止と安全性を目指して-. 手術 52 : 1477-1483, 1998.
14) Yasuda A, et al : A newly modified esophagogastrostomy with a reliable angle of His by placing a gastric tube in the lower mediastinum in laparoscopy-assisted proximal gastrectomy. Gastric Cancer 18 : 850-858, 2015.
15) Shaibu Z, et al : Effects of reconstruction techniques after proximal gastrectomy : a systematic review and meta-analysis. World J Surg Oncol 18 : 171, 2020.
P.201 掲載の参考文献
1) Hasegawa H, et al : Surgical outcomes of gastroenterological surgery in Japan : Report of the National Clinical Database 2011-2017. Ann Gastroenterol Surg 3 : 426-450, 2019.
2) Kodera Y, et al : Introducing laparoscopic total gastrectomy for gastric cancer in general practice : a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer 22 : 202-213, 2019.
3) Miura S, et al : Esophagojejunostomy With Linear Staplers in Laparoscopic Total Gastrectomy : Experience With 168 Cases in 5 Consecutive Years. Surg Laparosc Endosc Percutan Tech 27 : e101-e107, 2017.
5) Inaba K, et al : Overlap method : novel intracorporeal esophagojejunostomy after laparoscopic total gastrectomy. J Am Coll Surg 211 : e25-29, 2010.
6) Lee SW, et al : The crossover technique for intracorporeal esophagojejunostomy following laparoscopic total gastrectomy : a simple and safe technique using a linear stapler and two barbed sutures. Surg Endosc 33 : 1386-1393, 2019.
7) Watanabe M, et al : Clinical Significance of Splenic Hilar Dissection with Splenectomy in Advanced Proximal Gastric Cancer : An Analysis at a Single Institution in Japan. World J Surg 40 : 1165-1171, 2016.
8) Maezawa Y, et al : Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. Gastric Cancer 21 : 569-572, 2018.
9) Yura M, et al : The Therapeutic Survival Benefit of Splenic Hilar Nodal Dissection for Advanced Proximal Gastric Cancer Invading the Greater Curvature. Ann Surg Oncol 26 : 829-835, 2019.
10) Kano Y, et al : Therapeutic value of splenectomy to dissect splenic hilar lymph nodes for type 4 gastric cancer involving the greater curvature, compared with other types. Gastric Cancer 23 : 927-936, 2020.
11) Lin JX, et al : Is it necessary to dissect the posterior lymph nodes along the splenic vessels during total gastrectomy with D2 lymphadenectomy for advanced gastric cancer? Eur J Surg Oncol 43 : 2357-2365, 2017.
12) Sun LM, et al : Splenectomy and increased subsequent cancer risk : a nationwide population-based cohort study. Am J Surg 210 : 243-251, 2015.
13) Shi LZ, et al : Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7 : 12335, 2016.
P.206 掲載の参考文献
2) Kurokawa Y, et al : Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors : A Prospective Nationwide Multicenter Study. Ann Surg 274 : 120-127, 2021.
3) Mine S, et al : Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers : a prospective nationwide multicenter study. Gastric Cancer, 2021. (DOI : 10.1007/s10120-021-01255-9)
6) 胃癌治療ガイドライン 医師用 [第4版] (日本胃癌学会編). 金原出版, 2014.
7) 胃癌治療ガイドライン 医師用 [第6版] (日本胃癌学会編). 金原出版, 2021.
P.213 掲載の参考文献
1) 竹内裕也, ほか : 食道胃接合部癌に対するリンパ節郭清範囲. 臨床外科 73 : 536-539, 2018.
3) Kurokawa Y, et al : Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors : A Prospective Nationwide Multicenter Study. Ann Surg 274 : 120-127, 2021.
4) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
5) 平松良浩, ほか : 進行食道胃接合部癌へのアプローチ. -リンパ節郭清を中心に. 外科 82 : 1129-1133, 2020.
P.220 掲載の参考文献
1) Kim HI, et al : Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg 263 : 103-109, 2016.
2) Uyama I, et al : Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer : a multi-institutional prospective single-arm study. Gastric Cancer 22 : 377-385, 2019.
3) Lu J, et al : Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer : A Randomized Controlled Trial. Ann Surg 273 : 858-867, 2021.
4) Ojima T, et al : Short-term Outcomes of Robotic Gastrectomy vs Laparoscopic Gastrectomy for Patients With Gastric Cancer : A Randomized Clinical Trial. JAMA Surg 156 : 954-963, 2021.
5) Guerrini GP, et al : Robotic versus laparoscopic gastrectomy for gastric cancer : The largest metaanalysis. Int J Surg 82 : 210-228, 2020.
6) 胃癌治療ガイドライン医師用 [改訂第6版] (日本胃癌学会編), 金原出版, 2021.
7) Kikuchi K, et al : Challenges in improving the minimal invasiveness of the surgical treatment for gastric cancer using robotic technology. Ann Gastroenterol Surg 5 : 604-613, 2021.
P.225 掲載の参考文献
2) Tsuburaya A, et al : Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101 : 653-660, 2014.
3) Ito S, et al : A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis : JCOG1002. Gastric Cancer 20 : 322-331, 2017.
4) Takahari D, et al : Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer 23 : 293-299, 2020.
5) Iwasaki Y, et al : Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501) : an open-label, phase 3, randomized controlled trial. Gastric Cancer 24 : 492-502, 2021.
6) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26 : 141-148, 2015.
7) Matsumoto T, et al : HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer 18 : 467-475, 2015.
8) Sato Y, et al : A Phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704). Future Oncol 16 : 31-38, 2020.
9) Park I, et al : A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 72 : 815-823, 2013.
10) Sasako M, et al : D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 : 453-462, 2008.
12) Park IH, et al : Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 67 : 127-136, 2011.
13) Ri M, et al : Favorable Outcomes of Neoadjuvant Chemotherapy and Limited Para-Aortic Lymph Node Dissection for Advanced Gastric Cancer with Para-aortic Lymph Node Metastasis. World J Surg 45 : 2849-2859, 2021.
14) Inoue K, et al : Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol 38 : 143-149, 2012.
15) Katayama H, et al : An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer 22 : 1301-1307, 2019.
P.233 掲載の参考文献
1) 胃癌治療ガイドライン医師用 [第6版] (日本胃癌学会編), 金原出版, 2021.
2) 胃癌治療ガイドライン医師用 [第4版] (日本胃癌学会編), 金原出版, 2014.
3) 胃癌治療ガイドライン医師用 [第5版] (日本胃癌学会編), 金原出版, 2018.
4) Fujitani K, et al : Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA) : a phase 3, randomised controlled trial. Lancet Oncol 17 : 309-318, 2016.
6) Yamaguchi K, et al : The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21 : 315-323, 2018.
7) Terashima M, et al : International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1) [2018 ASCO Annual Meeting Abstract]. J Clin Oncol 36 (15 Suppl) : 4042, 2018.
8) Yoshida K, et al : International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg, 2021. (DOI : 10.1002/ags3.12515)
9) Yamaguchi T, et al : Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a) : A Multicenter Retrospective Study. Ann Surg Oncol 27 : 284-292, 2020.
10) Janjigian YY, et al : First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649) : a randomised, open-label, phase 3 trial. Lancet 398 : 27-40, 2021.
P.238 掲載の参考文献
1) 胃癌治療ガイドライン医師用 [第6版] (日本胃癌学会編), 金原出版, 2021.
3) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26 : 141-148, 2015.
4) Fujitani K, et al : Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open 1 : 165-174, 2017.
5) Terashima M, et al : Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. Gastric Cancer 24 : 224-231, 2021.
6) Fujitani K, et al : Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA) : a phase 3, randomised controlled trial. Lancet Oncol 17 : 309-318, 2016.
8) Yamaguchi K, et al : The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21 : 315-323, 2018.
9) Yoshida K, et al ; CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO) : International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 00 : 1-14, 2021. (DOI : 10.1002/ags3.12515)
10) 伏田幸夫, ほか : 胃癌腹膜播種における腹腔内化学療法の有用性と新規抗癌剤の貢献度. 癌と化学療法 32 : 1691-1694, 2005.
12) Ishigami H, et al : Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21 : 67-70, 2010.
13) Ishigami H, et al : Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis : PHOENIXGC Trial. J Clin Oncol 36 : 1922-1929, 2018.
14) Ishigami H, et al : Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20 : 128-134, 2017.
15) Ishigami H, et al : Gastrectomy after response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology. Ann Oncol 28 (Suppl 5) : v225, 2017.
P.244 掲載の参考文献
1) Takemura N, et al : Long-term outcomes after surgical resection for gastric cancer liver metastasis : an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 397 : 951-957, 2012.
2) Aizawa M, et al : Clinical benefit of surgical management for gastric cancer with synchronous liver metastasis. Hepatogastroenterology 61 : 1439-1445, 2014.
3) Kinoshita T, et al : Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg 102 : 102-107, 2015.
4) Tiberio GA, et al : Gastric cancer and synchronous hepatic metastases : is it possible to recognize candidates to R0 resection? Ann Surg Oncol 22 : 589-596, 2015.
5) Oki E, et al : Surgical treatment of liver metastasis of gastric cancer : a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 19 : 968-976, 2016.
6) Guner A, et al : Liver-directed treatments for liver metastasis from gastric adenocarcinoma : comparison between liver resection and radiofrequency ablation. Gastric Cancer 19 : 951-960, 2016.
7) Song A, et al : Surgical resection for hepatic metastasis from gastric cancer : a multi-institution study. Oncotarget 8 : 71147-71153, 2017.
8) Ministrini S, et al : Surgical treatment of hepatic metastases from astric cancer. Updates Surg 70 : 273-278, 2018.
9) Sano K, et al : Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases : a multicenter analysis. J Hepatobiliary Pancreat Sci 25 : 465-475, 2018.
10) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
11) Shirasu H, et al : Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer 21 : 338-344, 2018.
12) 転移性肝がん診療ガイドライン (日本肝胆膵外科学会主催, 日本癌治療学会, 日本胃癌学会, ほか共催), 医学図書出版, 2021.
13) Takemura N, et al : Long-term results of hepatic resection for non-colorectal, non-neuroendocrine liver metastasis. Hepatogastroenterology 60 : 1705-1712, 2013.
15) Takemura N, et al : Proposal of new treatment algorithm for gastric cancer liver metastases ; Upfront surgery or conversion surgery? Glob Health Med, 2021. (DOI : 10.35772/ghm.2021.01102)
P.249 掲載の参考文献
1) Guidance for Industry. Patient-Reported Outcome Measures : Use in Medical Product Development to Support Labeling Claims. [https://www.fda.gov/media/77832/download]
2) Nakane Y, et al : A randomized clinical trial of pouch reconstruction after total gastrectomy for cancer : which is the better technique, Roux-en-Y or interposition? Hepatogastroenterology 48 : 903-907, 2001.
3) Borgaonkar MR, Irvine EJ : Quality of life measurement in gastrointestinal and liver disorders. Gut 47 : 444-454, 2000.
4) Kono K, et al : Improved quality of life with jejunal pouch reconstruction after total gastrectomy. Am J Surg 185 : 150-154, 2003.
5) Kobayashi D, et al : Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg 35 : 357-364, 2011.
7) Nakada K, et al : Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS) -45 : newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients. Gastric Cancer 18 : 147-158, 2015.
8) Honda M, et al : Development and validation of a symptom scale to evaluate postoperative patients with esophagogastric cancer. J Am Coll Surg 219 : 895-903, 2014.
9) Turner-Bowker DM, et al : Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res 12 : 1003-1012, 2003.
10) Svedlund J, et al : GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33 : 129-134, 1988.
11) Nakada K, et al : Factors affecting the quality of life of patients after gastrectomy as assessed using the newly developed PGSAS-45 scale : A nationwide multi-institutional study. World J Gastroenterol 22 : 8978-8990, 2016.
12) 小林和道 : Patient Reported Outcomeと新薬開発. JPMA News Letter 153 : 48-51, 2013.
P.257 掲載の参考文献
1) GLOBOCAN Cancer Incidence and Mortality Worldwide, 2020.
2) GLOBOCAN Cancer Incidence and Mortality Worldwide, 2012.
3) Ohtsu A, et al : Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24 : 2188-2196, 2006.
5) Van Cutsem E, et al : Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30 : 2119-2127, 2012.
6) Watatsuki T, et al : Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer (abstract). J Clin Oncol 30 (15 suppl) : 4026, 2012.
7) 胃癌治療ガイドライン 2021年7月改訂 [第6版] (日本胃癌学会編), 金原出版, 2021.
P.262 掲載の参考文献
1) 胃癌治療ガイドライン医師用 2021年7月改訂 [第6版] (日本胃癌学会編), 金原出版, 2021.
2) 乳癌・胃癌HER2病理診断ガイドライン [第2版] (日本病理学会編), 金原出版, 2021.
3) Van Cutsem E, et al : HER2 screening data from ToGA : targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18 : 476-484, 2015.
4) Akagi K, et al : Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112 : 1105-1113, 2021.
5) Takashima A, et al : Survival after failure of first-line chemotherapy in advanced gastric cancer patients : differences between Japan and the rest of the world. Jpn J Clin Oncol 47 : 583-589, 2017.
6) Iizumi S, et al : Survival impact of post-progression chemotherapy in advanced gastric cancer : systematic review and meta-analysis. Cancer Chemother Pharmacol 81 : 981-989, 2018.
7) Shitara K, et al : Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer 14 : 155-160, 2011.
8) Ueno M, et al : Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics : an analysis in real-world setting. J Gastrointest Oncol 10 : 957-964, 2019.
9) Iwasa S, et al : Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol 25 : 1223-1232, 2020.
P.266 掲載の参考文献
2) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26 : 141-148, 2015.
4) Nakajima TE, et al : Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer 23 : 677-688, 2020.
5) Oh SY, et al : A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37 : 930-935, 2007.
6) Janjigian YY, et al : First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649) : a randomised, open-label, phase 3 trial. Lancet 398 : 27-40, 2021.
7) Boku N, et al : Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer : ATTRACTION-4 (ONO-4538-37) study. Ann Oncol 31 (Suppl 4) : S1192, 2020. (DOI : 10.1016/j.annonc.2020.08.2297)
8) Janjigian YY, et al : First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer : an open-label, single-arm, phase 2 trial. Lancet Oncol 21 : 821-831, 2020.
9) Lo Russo G, et al : Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res 25 : 989-999, 2019.
10) Fukuoka S, et al : Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer : An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol 38 : 2053-2061, 2020.
11) Kawazoe A, et al : Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706) : an open-label, single-arm, phase 2 trial. Lancet Oncol 21 : 1057-1065, 2020.
12) Sahin U, et al : FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32 : 609-619, 2021.
13) Bahleda R, et al : Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol 31 : 1405-1412, 2020.
14) Catenacci DV, et al : FIGHT : A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol 39 (15 Suppl) : 4010, 2021. (DOI : 10.1200/JCO.2021.39.15 suppl.4010)
P.273 掲載の参考文献
4) Hirata K, et al : A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT). J Clin Oncol 40 (4 suppl) : 280, 2022.
5) Fuchs CS, et al : Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 : 31-39, 2014.
6) Shitara K, et al : Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial. Lancet 392 : 123-133, 2018.
7) Makiyama A, et al : Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer : WJOG7112G (T-ACT Study). J Clin Oncol 38 : 1919-1927, 2020.
8) Diaz LA, et al : Pembrolizumab in microsatellite instability high cancers : Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies. Ann Oncol 30 (suppl 5) : v475, 2019.
9) Bang YJ, et al : Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD) : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1637-1651, 2017.
10) Chen LT, et al : A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2) : Three-year update data. J Clin Oncol 38 (4 suppl) : 383, 2020.
11) Matsushima T, et al : REVIVE study : A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC). J Clin Oncol 40 (4 suppl) : 257, 2022.
12) Shitara K, et al : Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19 : 1437-1448, 2018.
13) Kawazoe A, et al : Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer : an open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 6 : 209-217, 2021.
14) Shitara K, et al : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 382 : 2419-2430, 2020.
15) Yamaguchi K, et al : Trastuzumab deruxtecan (T-DXd ; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma : Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol 31 (suppl 4) : S899-S900, 2020.
P.279 掲載の参考文献
1) NCCN Guidelines Version 2. 2021. Gastric Cancer, 2021.
2) Smyth EC, et al : Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 : v38-v49, 2016.
3) ESMO Guidelines Committee : ESMO Guidelines. eUpdate?Gastric Cancer Treatment Recommendations. Published : 4 November 2019.
4) Tsuburaya A, et al : Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101 : 653-660, 2014.
5) 胃癌治療ガイドライン 2021年7月改訂 [第6版] (日本胃癌学会編), 金原出版, 2021.
6) Terashima M, et al : Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results : Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer 22 : 1044-1052, 2019.
7) Fukagawa T, et al : A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer 21 : 68-73, 2018.
8) Nakamura K, et al : Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A). Jpn J Clin Oncol 42 : 896-902, 2012.
9) Ronellenfitsch U, et al : Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma : Pooled analysis of individual patient data from randomized controlled trials. Eur J Cancer 123 : 101-111, 2019.
10) Al-Batran SE, et al : Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2/3 trial. Lancet 393 : 1948-1957, 2019.
12) Kang YK, et al : PRODIGY : A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 39 : 2903-2913, 2021.
13) Ji J, et al : Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy : A randomized phase III trial (RESOLVE trial). ESMO 2019 Congress. LBA42. Ann Oncol 30 (Suppl 5) : v877, 2019.
14) Chao J, et al : Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol 7 : 895-902, 2021.
15) Vos EL, et al : The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival. J Clin Oncol 39 (3 suppl) : 244, 2021.
16) Pietrantonio F, et al : Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol 37 : 3392-3400, 2019.
17) Smyth EC, et al : Mismatch Repair Deficiency, Microsatellite Instability, and Survival : An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 3 : 1197-1203, 2017.
18) Hofheinz RD, et al : Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma : Final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 38 (15 suppl) : 4502, 2020.
19) Reinert T, et al : Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 5 : 1124-1131, 2019.
P.286 掲載の参考文献
1) Iwasaki Y, et al : Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501) : an open-label, phase 3, randomized controlled trial. Gastric Cancer 24 : 492-502, 2021.
2) Wang XZ, et al : Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 12 : 37-53, 2020.
3) Diasio RB : Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park) 14 (10 Suppl 9) : 19-23, 2000.
4) Terashima M, et al : Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22 : 761-768, 2002.
5) Napieralski R, et al : Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11 : 3025-3031, 2005.
6) Wang W, et al : Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 64 : 8167-8176, 2004.
7) Wang D, et al : High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer : a meta-analysis. Int J Biol Markers 31 : e101-109, 2016.
9) Sugasawa K : Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat Res 685 : 29-37, 2010.
11) Wei J, et al : ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98 : 1398-1402, 2008.
12) Fareed KR, et al : Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102 : 1600-1607, 2010.
13) Kwon HC, et al : Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione Stransferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 : 504-509, 2007.
14) Hirakawa M, et al : A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer : nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 71 : 789-797, 2013.
15) Wang X, et al : BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Med Oncol 31 : 249, 2014.
16) Jeong SH, et al : Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci 56 : 131-138, 2011.
17) Kubo T, et al : BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer. Gastric Cancer 19 : 827-838, 2016.
18) Wu N, et al : High BIM mRNA levels are associated with longer survival in advanced gastric cancer. Oncol Lett 13 : 1826-1834, 2017.
19) Nakagawa T, et al : JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8. Gastric Cancer 23 : 426-436, 2020.
20) Pietrantonio F, et al : Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol 37 : 3392-3400, 2019.
21) Hashimoto T, et al : Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer 22 : 785-792, 2019.
22) Haag GM, et al : Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer 144 : 1697-1703, 2019.
23) Poursheikhani A, et al : Non-coding RNAs underlying chemoresistance in gastric cancer. Cell Oncol (Dordr) 43 : 961-988, 2020.
24) Liu K, et al : Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 10 : 225, 2012.
25) Tan B, et al : Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. J Clin Lab Anal 32 : e22363, 2018.
26) Butera G, et al : Autocrine mechanisms of cancer chemoresistance. Semin Cell Dev Biol 78 : 3-12, 2018.
27) Zhang H, et al : CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemoresistance in gastric cancer. Mol Cancer 19 : 43, 2020.
28) Wang M, et al : Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p. Int J Oncol 54 : 326-338, 2019.
P.292 掲載の参考文献
1) 胃癌治療ガイドライン医師用 [2021年7月 改訂第6版] (日本胃癌学会編), 金原出版, 2021.
2) Fujitani K, et al : Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA) : a phase 3, randomised controlled trial. Lancet Oncol 17 : 309-318, 2016.
4) Terashima M, et al : International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). J Clin Oncol 36 (suppl 15) : 4042 (abstr), 2018.
5) Al-Batran SE, et al : Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer : The AIO-FLOT3 Trial. JAMA Oncol 3 : 1237-1244, 2017.
6) Sasako M, et al : D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 : 453-462, 2008.
7) Tsuburaya A, et al : Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101 : 653-660, 2014.
8) Takahari D, et al : Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer 23 : 293-299, 2020.
9) Katayama H, et al : An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer 22 : 1301-1307, 2019.
10) 松本友寛, ほか : 高度リンパ節転移 (Bulky N2 or cN3) を伴う進行胃癌におけるHER2発現陽性割合の検討 (JCOG1005-A). 第84回日本胃癌学会総会, 2012.
11) Gong Y, et al : Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis : A Meta-Analysis. J Surg Res 245 : 234-243, 2020.
12) Kodera Y, et al : Surgical resection of hepatic metastasis from gastric cancer : a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer 17 : 206-212, 2014.
13) Shirasu H, et al : Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer 21 : 338-344, 2018.
14) Ishigami H, et al : Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20 : 128-134, 2017.
15) Kitayama J, et al : Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 21 : 539-546, 2014.
16) Imano M, et al : Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg 16 : 2190-2196, 2012.
17) Fujiwara Y, et al : Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol 18 : 3726-3731, 2011.
18) Chan DYS, et al : Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? J Gastrointest Surg 21 : 425-433, 2017.
P.296 掲載の参考文献
1) Fukagawa T : Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg 3 : 496-505, 2019.
2) 深川剛生, ほか : 腹腔洗浄細胞診病理に期待すること. 病理と臨床 39 : 45-49, 2021.
6) Iwasaki Y, et al : Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501) : an open-label, phase 3, randomized controlled trial. Gastric Cancer 24 : 492-502, 2021.
7) Yamaguchi T, et al : Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a) : a multi-institutional retrospective study. Gastric Cancer 24 : 701-709, 2021.
8) Yasufuku I, et al : Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer 23 : 319-327, 2020.
10) Yamaguchi T, et al : Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a) : A Multicenter Retrospective Study. Ann Surg Oncol 27 : 284-292, 2020.
11) Ishigami H, et al : Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis : PHOENIX-GC Trial. J Clin Oncol 36 : 1922-1929, 2018.
12) Ishigami H, et al : Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer : PHOENIX-GC2 Trial. J Clin Med 10 : 5666, 2021. (DOI : 10.3390/jcm10235666)
P.303 掲載の参考文献
1) Smalley SR, et al : Updated analysis of SWOG-directed intergroup study 0116 : a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30 : 2327-2333, 2012.
7) Takahari D, et al : Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 67 : 1423-1428, 2011.
8) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26 : 141-148, 2015.
9) Nakamura Y, et al : Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Ann Surg Oncol 26 : 465-472, 2019.
10) Grothey A, et al : Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378 : 1177-1188, 2018.
11) Yoshikawa T, et al : Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]) : an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 4 : 208-216, 2019.
12) Yoshida K, et al : Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer : Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol 37 : 1296-1304, 2019.
14) Park SH, et al : A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection : the ARTIST 2 trial. Ann Oncol 32 : 368-374, 2021.
15) Pietrantonio F, et al : Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol 37 : 3392-3400, 2019.
P.310 掲載の参考文献
1) Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 : 209-249, 2021.
3) Chua YJ, Cunningham D : The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer : implications for clinical practice. Ann Surg Oncol 14 : 2687-2690, 2007.
4) Fuchs CS, Mayer RJ : Gastric carcinoma. N Engl J Med 333 : 32-41, 1995.
6) Al-Batran SE, et al : Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2/3 trial. Lancet 393 : 1948-1957, 2019.
7) Sakuramoto S, et al : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357, 1810-1820, 2007.
10) Tsuburaya A, et al : Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101 : 653-660, 2014.
11) Ito S, et al : A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis : JCOG1002. Gastric Cancer 20 : 322-331, 2017.
12) Iwasaki Y, et al : Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501) : an open-label, phase 3, randomized controlled trial. Gastric Cancer 24 : 492-502, 2021.
13) Kang YK, et al : PRODIGY : A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 39 : 2903-2913, 2021.
14) Zhang X, et al : Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) : an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22 : 1081-1092, 2021.
15) Cunningham D, et al : Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03) : primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 18 : 357-370, 2017.
P.316 掲載の参考文献
1) van Hagen P, et al : Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366 : 2074-2084, 2012.
5) Al-Batran SE, et al : Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2/3 trial. Lancet 393 : 1948-1957, 2019.
6) Vosmik M, et al : Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas : State of the Art and Aspects of Predictive Factors. Cancers (Basel) 13 : 4591, 2021.
7) Cats A, et al : Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS) : an international, open-label, randomised phase 3 trial. Lancet Oncol 19 : 616-628, 2018.
8) Stahl M, et al : Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27 : 851-856, 2009.
9) Reynolds JV, et al : Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study) : Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452) [2021 ASCO Annual Meeting Abstract]. J Clin Oncol 39 (15 Suppl) : 4004, 2021.
11) Zhang X, et al : Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) : an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22 : 1081-1092, 2021.
12) Kang YK, et al : PRODIGY : A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 39 : 2903-2913, 2021.
13) Hofheinz RD, et al : Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma : Final results of the PETRARCA multicenter randomized phase II trial of the AIO [2020 ASCO Annual Meeting Abstract]. J Clin Oncol 38 (15 Suppl) : 4502, 2020.
14) Al-Batran SE, et al : Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) : Results of the phase II-portion-A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM [2020 ASCO Annual Meeting Abstract]. J Clin Oncol 38 (15 Suppl) : 4501, 2020.
15) Kelly RJ, et al : Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384 : 1191-1203, 2021.
16) Pietrantonio F, et al : Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol 37 : 3392-3400, 2019.
P.321 掲載の参考文献
2) Shitara K, et al : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 382 : 2419-2430, 2020.
4) Tabernero J, et al : Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 29 : 602-609, 2018.
5) Catenacci DV, et al : Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer : FIGHT Phase III study design. Future Oncol 15 : 2073-2082, 2019.
6) Sahin U, et al : FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32 : 609-619, 2021.
7) Bang YJ, et al : Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD) : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1637-1651, 2017.
8) Catenacci DVT, et al : Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1467-1482, 2017.
9) Marabelle A, et al : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer : Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38 : 1-10, 2020.
10) Shitara K, et al : Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial. Lancet 392 : 123-133, 2018.
P.328 掲載の参考文献
1) Lim S, et al : Development and progression of cancer cachexia : Perspectives from bench to bedside. Sports Med Health Sci 2 : 177-185, 2020.
2) Marshall KM, et al : Prevalence of malnutrition and impact on clinical outcomes in cancer services : A comparison of two time points. Clin Nutr 38 : 644-651, 2019.
3) Cederholm T, et al : GLIM criteria for the diagnosis of malnutrition?A consensus report from the global clinical nutrition community. Clin Nutr 38 : 1-9, 2019.
4) Sugiyama K, et al : Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. Anticancer Res 38 : 5859-5866, 2018.
5) Ock CY, et al : Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer 19 : 597-606, 2016.
6) Fuchs CS, et al : Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 : 31-39, 2014.
7) Mizukami T, et al : Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment. Nutr Cancer, 2021. (DOI : 10.1080/01635581)
8) Mansoor W, et al : Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer : Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies. Oncologist 26 : e1538-e1547, 2021.
9) Guo ZQ, et al : Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. Support Care Cancer 28 : 373-380, 2020.
10) Li H, et al : The incidence and impact of weight loss with cachexia in gastric cancer patients. J Clin Oncol 33 (15 suppl) : e20644, 2015. (DOI : 10.1200/jco.2015.33.15_suppl.e20644)
11) Qiu M, et al : Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer 23 : 1933-1939, 2015.
12) Shusterman M, et al : Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies. J Clin Oncol 38 (15 suppl) : 12090, 2020. (DOI : 10.1200/JCO.2020.38.15_suppl.12090)
14) Hamauchi S, et al : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125 : 4294-4302, 2019.
P.333 掲載の参考文献
1) 内閣府 : 令和2年版高齢社会白書. [https://www8.cao.go.jp/kourei/whitepaper/w-2020/html/zenbun/s1_1_1.html] (2022年1月閲覧)
2) 日本老年学会, 日本老年医学会 : 高齢者に関する定義検討ワーキンググループ報告書, 2017. [https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20170410_01_01.pdf] (2022年1月閲覧)
3) 国立がん研究センター : がん種別統計情報がん情報サービス : 胃. [https://ganjoho.jp/reg_stat/statistics/stat/cancer/5_stomach.html] (2022年1月閲覧)
4) 日本老年医学会 : フレイルに関する日本老年医学会からのステートメント, 2014. [https://jpn-geriat-soc.or.jp/info/topics/pdf/20140513_01_01.pdf] (2022年1月閲覧)
5) Sugawara K, et al : Poor nutritional status and sarcopenia influences survival outcomes in gastric carcinoma patients undergoing radical surgery. Eur J Surg Oncol 46 : 1963-1970, 2020.
6) 厚生労働省 : 令和2年簡易生命表の概況主な年齢の平均余命. [https://www.mhlw.go.jp/toukei/saikin/hw/life/life20/dl/life18-02.pdf] (2022年1月閲覧)
7) Takeshita H, et al : Surgical outcomes of gastrectomy for elderly patients with gastric cancer. World J Surg 37 : 2891-2898, 2013.
8) Wakahara T, et al : Impact of Gastric Cancer Surgery in Elderly Patients. Oncology 94 : 79-84, 2018.
9) Cho GS, et al : Multicentre study of the safety of laparoscopic subtotal gastrectomy for gastric cancer in the elderly. Br J Surg 96 : 1437-1442, 2009.
10) Inokuchi M, et al : Feasibility of laparoscopic gastrectomy for patients with poor physical status : a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer 23 : 310-318, 2020.
11) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), p23, 金原出版, 2021.
13) Mitsui T, et al : Non-exposed endoscopic wall-inversion surgery as a novel partial gastrectomy technique. Gastric Cancer 17 : 594-599, 2014.
P.339 掲載の参考文献
1) 胃癌治療ガイドライン 医師用 [第6版] (日本胃癌学会編), 金原出版, 2021.
2) 日本臨床腫瘍研究グループJCOG ポリシーNo.39 高齢者研究. [http://www.jcog.jp/basic/policy/A_020_0010_39.pdf]
6) Yamada Y, et al : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26 : 141-148, 2015.
7) Bando H, et al : Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19 : 919-926, 2016.
8) Hwang IG, et al : A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 8 : 170-175, 2017.
9) Choi IS, et al : A randomized phase III study to compare efficacy and safety between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10). Ann Oncol 32 (supple 5) : S1041 (abst 1374P), 2021.
10) Janjigian YY, et al : First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649) : a randomised, open-label, phase 3 trial. Lancet 398 : 27-40, 2021.
11) Kang YK, et al : Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4) : a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23 : 234-247, 2022.
13) Jatoi A, et al : Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach : a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 36 : 601-606, 2010.
14) Lichtman SM, et al : International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43 : 14-34, 2007.
15) 厚生労働省 : 平成23年国民健康・栄養調査. [www.mhlw.go.jp/toukei/itiran/gaiyo/k-eisei.html]
16) Boku N, et al : Clinicopathological characteristics of gastric cancer in elderly patients. Gan To Kagaku Ryoho 33 : 1099-1103, 2006.
17) 国立社会保障・人口問題研究所 : 日本の世帯数の将来推計 (都道府県別推計) (2014年4月推計).
19) 高齢者のがん薬物療法ガイドライン (日本臨床腫瘍学会/日本癌治療学会編), 南江堂, 2019.
P.345 掲載の参考文献
1) 小野裕之, ほか : 胃癌に対するESD/EMRガイドライン (第2版). 日本消化器内視鏡学会雑誌 62 : 275-290, 2020.
2) 胃癌治療ガイドライン [第6版] (日本胃癌学会編), 金原出版, 2021.
3) 胃癌治療ガイドライン [第5版] (日本胃癌学会編), 金原出版, 2018.
4) Kunisaki C, et al : Comparison of surgical outcomes of gastric cancer in elderly and middle-aged patients. Am J Surg 191 : 216-224, 2006.
5) Nunobe S, et al : Surgical outcomes of elderly patients with Stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer 23 : 328-338, 2020.
7) Watanabe M, et al : Total gastrectomy risk model : data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg 260 : 1034-1039, 2014.
9) Watanabe K, et al : Endoscopic submucosal dissection for early gastric cancer in very elderly patients age 85 or older. Endosc Int Open 5 : E17-E24, 2017.
10) Yang TC, et al : Clinical Outcomes and Complications of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasms in the Elderly. Medicine (Baltimore) 94 : e1964, 2015.
11) Yamaguchi H, et al : Impact of gastric endoscopic submucosal dissection in elderly patients : The latest single center large cohort study with a review of the literature. Medicine (Baltimore) 98 : e14842, 2019.
14) Charlson ME, et al : A new method of classifying prognostic comorbidity in longitudinal studies : development and validation. J Chronic Dis 40 : 373-383, 1987.
15) Quan H, et al : Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173 : 676-682, 2011.
16) 小野寺時夫, ほか : Stage IV・V (V は大腸癌) 消化器癌の非治癒切除・姑息手術に対するTPNの適応と限界. 日本外科学会雑誌85 : 1001-1005, 1984.
17) de Ulibarri JI, et al : CONUT : a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20 : 38-45, 2005.
18) Son YW, et al : Efficacy and safety of endoscopic submucosal dissection for gastric epithelial neoplasia in elderly patients aged 80 years and older. Aging Clin Exp Res 31 : 1833-1838, 2019.
19) Sekiguchi M, et al : Clinical outcomes and prognostic factors in gastric cancer patients aged≧85 years undergoing endoscopic submucosal dissection. Gastrointest Endosc 85 : 963-972, 2017.
20) Yoshifuku Y, et al : Long-term prognosis after endoscopic submucosal dissection for early gastric cancer in super-elderly patients. Surg Endosc 30 : 4321-4329, 2016.
22) Gotoda T, et al : Incidence of lymph node metastasis from early gastric cancer : estimation with a large number of cases at two large centers. Gastric Cancer 3 : 219-225, 2000.
23) Kishida Y, et al : Endoscopic submucosal dissection versus surgery in elderly patients with early gastric cancer of relative indication for endoscopic resection. Dig Endosc, 2021. (DOI : 10.1111/den.14105)
24) Toya Y, et al : Long-term outcomes and prognostic factors with non-curative endoscopic submucosal dissection for gastric cancer in elderly patients aged ≧ 75 years. Gastric Cancer 22 : 838-844, 2019.
P.353 掲載の参考文献
2) 佐藤真 : 胃癌患者の栄養評価に関する臨床的研究-術前栄養状態の計量化による術後合併症発生予測指数の作成. 日本外科学会雑誌 83 : p66-77, 1982.
3) Iwasa M : [Nutritional assessment of patients with esophageal cancer. "Nutritional Assessment Index (NAI)" to estimate nutritional conditions in pre-and postoperative period]. Nihon Geka Gakkai Zasshi 84 : 1031-1041, 1983.
4) Onodera T, et al : [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 85 : 1001-1005, 1984.
6) Murakami Y, et al : Combined analysis of the preoperative and postoperative prognostic nutritional index offers a precise predictor of the prognosis of patients with gastric cancer. Surg Today 48 : 395-403, 2018.
7) Sakurai K, et al : Predictive Potential of Preoperative Nutritional Status in Long-Term Outcome Projections for Patients with Gastric Cancer. Ann Surg Oncol 23 : 525-533, 2016.
8) Park SH, et al : Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. Eur J Surg Oncol 46 : 620-625, 2020.
9) Sugawara K, et al : Poor nutritional status and sarcopenia influences survival outcomes in gastric carcinoma patients undergoing radical surgery. Eur J Surg Oncol 46 : 1963-1970, 2020.
10) Luo Z, et al : Prognostic impact of preoperative prognostic nutritional index in resected advanced gastric cancer : A multicenter propensity score analysis. Eur J Surg Oncol 45 : 425-431, 2019.
11) Saito H, et al : Influence of prognostic nutritional index and tumor markers on survival in gastric cancer surgery patients. Langenbecks Arch Surg 402 : 501-507, 2017.
12) Sun J, et al : Value of the prognostic nutritional index in advanced gastric cancer treated with preoperative chemotherapy. J Surg Res 209 : 37-44, 2017.
13) Migita K, et al : The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol 20 : 2647-2654, 2013.
14) Migita K, et al : The prognostic significance of inflammation-based markers in patients with recurrent gastric cancer. Surg Today 48 : 282-291, 2018.
15) Namikawa T, et al : Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today 50 : 1486-1495, 2020.
16) Matsunaga T, et al : Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer : a propensity score matching analysis. BMC Surg 21 : 33, 2021.
17) Watanabe M, et al : Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg 36 : 1632-1639, 2012.
18) Hashimoto T, et al : Postoperative Long-Term Outcomes in Elderly Patients with Gastric Cancer and Risk Factors for Death from Other Diseases. World J Surg 43 : 2885-2893, 2019.
19) Sakurai K, et al : Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer. Ann Surg Oncol 23 : 3669-3676, 2016.
20) Sakurai K, et al : Long-term survival estimates in older patients with pathological stage I gastric cancer undergoing gastrectomy : Duocentric analysis of simplified scoring system. J Geriatr Oncol 10 : 604-609, 2019.
21) Sugawara K, et al : Pre- and post-operative low prognostic nutritional index influences survival in older patients with gastric carcinoma. J Geriatr Oncol 11 : 989-996, 2020.
22) Takama T, et al : Predictors of postoperative complications in elderly and oldest old patients with gastric cancer. Gastric Cancer 18 : 653-661, 2015.
23) Takahashi T, et al : The preoperative prognostic nutrition index is a prognostic indicator for survival in elderly gastric cancer patients after gastrectomy : a propensity score-matched analysis. Updates Surg 72 : 483-491, 2020.
24) 静脈経腸栄養ガイドライン第3版 (日本静脈経腸栄養学会編), p222, 照林社, 2013.
25) Weimann A, et al : ESPEN guideline : Clinical nutrition in surgery. Clin Nutr 36 : 623-650, 2017.
P.357 掲載の参考文献